Polar Asset Management Partners Inc. Madrigal Pharmaceuticals, Inc. Transaction History

Polar Asset Management Partners Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $48,160 - $94,852	-400 Reduced 3.88%	9,900 $2.29 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $788,616 - $1.22 Million	-5,400 Reduced 34.39%	10,300 $1.5 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $2.41 Million - $3.68 Million	11,800 Added 302.56%	15,700 $3.63 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $227,721 - $1.16 Million	3,900 New	3,900 $1.13 Million
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $3.06 Million - $5.29 Million	-52,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$78.35 - $105.02 $1.94 Million - $2.59 Million	24,700 Added 87.9%	52,800 $4.21 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $2.73 Million - $3.87 Million	28,100 New	28,100 $2.74 Million

297

21.9M

757K

370K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.72B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Polar Asset Management Partners Inc. with notifications on news.